Standard recommended medication cycle time for regorafenib

Regorafenib is a multi-target tyrosine kinase inhibitor used for a variety of advanced solid tumors, and its standard recommended medication cycle has been unanimously recognized in multiple international authoritative guidelines and drug inserts. The usual medication pattern is: take it orally once a day, 160mg each time (i.e. four 40mg tablets), take it continuously for 21 days, and then stop taking it for 7 days, for a total of 28 days as a complete treatment cycle. This "3 weeks of medication + 1 week of drug withdrawal" model has been widely used in clinical practice and is considered to be able to minimize the occurrence of adverse reactions while ensuring efficacy.

Specifically, patients usually take regorafenib on time every day during the first three weeks of a cycle, and it is recommended to take it at the same time every day after meals to reduce gastrointestinal adverse reactions and improve drug absorption efficiency. During the medication period, liver function, electrolytes, blood pressure, and blood routine indicators need to be closely monitored because the medication may cause side effects such as hypertension, hand-foot syndrome, proteinuria, and elevated liver enzymes. Pausing medication during the fourth week provides the patient with a short-term recovery period for the body to improve tolerance for the next cycle.

In addition, if the patient develops ≥ Grade 2 toxic reactions during treatment, such as severe skin reactions or liver function damage, the doctor may adjust the dose according to the situation, such as reducing it to 120 mg or 80 mg, or temporarily discontinuing the drug until the symptoms are relieved. If adverse reactions recur, further evaluation may be needed to determine whether continued regorafenib treatment is appropriate.

It is worth noting that although the recommended pattern of regorafenib administration per cycle is 21 days and 7 days off, some doctors in clinical practice make individualized adjustments based on the patient's specific condition and drug tolerance. In some patients with poor tolerance, a lower dose starting strategy may be adopted, such as the first dose being 80 mg and increasing to 160 mg weekly to reduce initial toxicity and improve compliance.

Reference materials:https://www.stivarga-us.com/